1.Correlation of IL-8 and IL-6 in prostatic fluid with serum prostate-specific antigen level in patients with benign prostatic hyperplasia complicated by prostatitis.
Xingfei REN ; Chunlei WU ; Qinnan YU ; Feng ZHU ; Pei LIU ; Huiqing ZHANG
Journal of Southern Medical University 2016;36(1):135-139
OBJECTIVETo investigate the correlation of the levels of interleukin-8 (IL-8) and IL-6 in the prostatic fluid with serum levels of serum prostate-specific antigen (PSA) in patients with benign prostatic hyperplasia (BPH) complicated by prostatitis.
METHODSA series of 211 patients undergoing surgery of BPH were divided into BPH group (n=75) and BPH with prostatitis group (n=136) according to the white blood cell count in the prostatic fluid. The clinical and laboratory findings were compared between the two groups, and stepwise regression analysis was used to assess the association of IL-8 and IL-6 with serum PSA level.
RESULTSNo significant differences were found in age, BMI, blood pressure, blood glucose, blood lipids, IPSS score, PSA-Ratio, or prostate volume between the two groups (P<0.05). The patients with prostatitis had significantly increased serum PSA and prostate fluid IL-8 and IL-6 levels compared with those without prostatitis (P<0.001). Multiple linear regression analysis showed that IL-8 and IL-6 levels and white blood cell count in the prostatic fluid were all positively correlated with serum PSA level.
CONCLUSIONProstatitis is an important risk factor for elevated serum PSA level in patients with BPH, and both IL-8 and IL-6 levels in the prostatic fluid are correlated with serum PSA level.
Body Fluids ; chemistry ; Humans ; Interleukin-6 ; chemistry ; Interleukin-8 ; chemistry ; Leukocyte Count ; Male ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; complications ; diagnosis ; Prostatitis ; complications ; diagnosis ; Regression Analysis ; Risk Factors
2.Expression of IL-33 in patients with systemic sclerosis and its correlation with TGF-β
Bintao SU ; Lan ZHAO ; Xingfei WU ; Xin CHEN ; Zunyi CHEN ; Botao YIN
Chinese Journal of Clinical Laboratory Science 2018;36(4):267-269
Objective To investigate the expressions of interleukin-33 (IL-33),soluble growth stimulation expressed gene 2 (sST2) and transforming growth factor β1 (TGF-β1) in the patients with systemic sclerosis (SSc) and their correlations.Methods Serum IL-33,sST2 and TGF-β1 levels from 25 SSc patients and 25 healthy controls were determined by an enzyme linked immunosorbent assay (ELISA).The expressions of IL-33 in the damaged skin tissue of SSc patients and normal skin tissue were detected with the immunohistochemical staining.Results Serum IL-33 and TGF-β1 levels in SSc patients were significantly higher than that in healthy controls (P < 0.05),and serum IL-33 levels were positively correlated with TGF-β1 levels in SSc patients (P < 0.05).Immunohistochemical staining results showed that the expression level of IL-33 in the damaged skin tissue of SSc patients were significantly higher than that in normal skin tissue (P < 0.05).However,there was no significant difference in the expression level of sST2 between SSc patinets and healthy controls.Conclusion Serum IL-33 levels in SSc patients increase significantly,which is correlated with the expression of TGF-β1,indicating that IL-33 may play an important role in the process of inflammation and fibrosis of SSc via the regulation of TGF-β1.
3.Improvement effect of arbutin on myocardial fibrosis model rats and its mechanism
Minghao ZHANG ; Xingfei WU ; Liujun WU ; Yanduo SHEN ; Jiale ZHANG ; Bingheng XIE ; Jinjin WANG
China Pharmacy 2024;35(5):529-535
OBJECTIVE To study the improvement effects of arbutin on myocardial fibrosis (MF) model rats and its mechanism. METHODS The network pharmacology was used to predict the potential target of arbutin in improving MF and molecular docking was used to validated. Totally 50 SD rats were given isoprenaline subcutaneously (5 mg/kg, once a day, for 14 consecutive days) to induce the MF model. Modeled rats were randomly divided into model group, captopril group (9 mg/kg), arbutin low-dose, medium-dose and high-dose groups (50, 100, 200 mg/kg), with 10 rats in each group. Another 10 healthy rats were included as normal group. Each group was given the corresponding drugs, once a day, for 28 consecutive days. Twenty-four hours after the final administration, electrocardiograms and heart-related indexes [heart weight index (HWI), left ventricular weight index (LVWI)] of rats were detected; the levels of creatine kinase (CK), lactate dehydrogenase (LDH), N-terminal pro-brain natriuretic peptide (NT-proBNP) and type Ⅰ collagen (Col Ⅰ) and Col Ⅲ were detected in myocardial tissue of rats; the pathological changes of myocardial tissue were observed, and protein and mRNA expressions of adenosine deaminase (ADA) and adenosine kinase (ADK) were detected in the myocardial tissue of rats. RESULTS The results of network pharmacology showed that the main targets of arbutin improving MF were ADA and ADK. The results of molecular docking showed that arbutin bind stably with ADA and ADK. The results of experimental verification showed that compared with model group, the amplitude of ST and T waves in electrocardiogram were improved in administration groups, and the symptoms of atrial flutter were alleviated; HWI (except for arbutin medium-dose group), LVWI, the levels of CK, LDH, NT-proBNP, Col Ⅰ and Col Ⅲ in the myocardial tissue of rats were decreased significantly (P<0.05); the degree of myocardial fibrosis in rats decreased; protein and mRNA expressions of ADA and ADK in the myocardial tissue were significantly increased (P<0.05). CONCLUSIONS Arbutin can improve cardiac fibrosis and cardiac function of MF model rats, the mechanism of which may be associated with up-regulating protein and mRNA expressions of ADA and ADK,influencing the nucleotide metabolism and collagen generation. zhangminghao@hactcm.edu.cn
4.Unbiased transcriptomic analyses reveal distinct effects of immune deficiency in CNS function with and without injury.
Dandan LUO ; Weihong GE ; Xiao HU ; Chen LI ; Chia-Ming LEE ; Liqiang ZHOU ; Zhourui WU ; Juehua YU ; Sheng LIN ; Jing YU ; Wei XU ; Lei CHEN ; Chong ZHANG ; Kun JIANG ; Xingfei ZHU ; Haotian LI ; Xinpei GAO ; Yanan GENG ; Bo JING ; Zhen WANG ; Changhong ZHENG ; Rongrong ZHU ; Qiao YAN ; Quan LIN ; Keqiang YE ; Yi E SUN ; Liming CHENG
Protein & Cell 2019;10(8):566-582
The mammalian central nervous system (CNS) is considered an immune privileged system as it is separated from the periphery by the blood brain barrier (BBB). Yet, immune functions have been postulated to heavily influence the functional state of the CNS, especially after injury or during neurodegeneration. There is controversy regarding whether adaptive immune responses are beneficial or detrimental to CNS injury repair. In this study, we utilized immunocompromised SCID mice and subjected them to spinal cord injury (SCI). We analyzed motor function, electrophysiology, histochemistry, and performed unbiased RNA-sequencing. SCID mice displayed improved CNS functional recovery compared to WT mice after SCI. Weighted gene-coexpression network analysis (WGCNA) of spinal cord transcriptomes revealed that SCID mice had reduced expression of immune function-related genes and heightened expression of neural transmission-related genes after SCI, which was confirmed by immunohistochemical analysis and was consistent with better functional recovery. Transcriptomic analyses also indicated heightened expression of neurotransmission-related genes before injury in SCID mice, suggesting that a steady state of immune-deficiency potentially led to CNS hyper-connectivity. Consequently, SCID mice without injury demonstrated worse performance in Morris water maze test. Taken together, not only reduced inflammation after injury but also dampened steady-state immune function without injury heightened the neurotransmission program, resulting in better or worse behavioral outcomes respectively. This study revealed the intricate relationship between immune and nervous systems, raising the possibility for therapeutic manipulation of neural function via immune modulation.